TerminatedPHASE1, PHASE2NCT01573286

Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure

Studying Congenital short bowel syndrome

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alberta Children's Hospital
Principal Investigator: David Sigalet, MD PhD
Alberta Children's Hospital
Intervention: Glucagon-Like Peptide 2(drug)
Enrollment: 13 enrolled
Eligibility: 18 years · All sexes
Timeline: 2012 – 2015

Study locations (4)

Alberta Children's Hospital, Calgary, Alberta, Canada
Stollery Children's Hospital, Edmonton, Alberta, Canada
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
Hospital for Sick Children, Toronto, Ontario, Canada

Collaborators

Stollery Children's Hospital · The Hospital for Sick Children · British Columbia Children's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01573286 on ClinicalTrials.gov

Other trials for Congenital short bowel syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT05535361
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
Eclipse Regenesis, Inc.

See all trials for Congenital short bowel syndrome →

← Back to all trials